Cota racial e estado: abolição do racismo ou direitos de raça?

O objetivo deste artigo é examinar a proposta corrente de racialização da população brasileira pelo Estado, com vistas a amparar programas de ação afirmativa para o atendimento específico daqueles que se autodenominarem negros. Analisa-se, inicialmente, o ressurgimento da noção de raça entre acadêmicos, políticos e militantes do anti-racismo, bem como as dificuldades de se delimitar quem é negro no Brasil. Em seguida, examina-se o modelo de cota racial dos Estados Unidos e seu apregoado sucesso. Por fim, busca-se avaliar até que ponto a instituição de cota racial no emprego e na universidade deveria se impor como a única opção política para aqueles que pretendem a abolição do racismo na sociedade brasileira.

Escola e status racial em Cachoeira do Campo/MG no século XIX

De acordo com uma documentação que contabilizou a população de Minas Gerais, nos anos de 1830, havia um predomínio dos negros entre os alunos das escolas de instrução elementar. Neste artigo, procuramos investigar os significados dessa experiência para a população negra através da confrontação de documentos censitários do distrito de Cachoeira do Campo/MG, que se encontrava no termo de Ouro Preto, na região central da província. O procedimento de análise ocorreu a partir da separação dos domicílios em que havia o registro de crianças frequentando escolas, em 1831. Em seguida, identificamos esses domicílios na documentação de 1838 analisando a situação dos indivíduos escolarizados e de seu grupo familiar. O intervalo de sete anos entre os documentos possibilitou a avaliação dos impactos da experiência escolar, revelando, entre outras coisas, que negros escolarizados eram preferencialmente designados como pardos e estes podiam mudar de status racial, passando até mesmo a ser classificados como brancos.

Racial inequalities and perinatal health in the southeast region of Brazil

Few studies are available about racial inequalities in perinatal health in Brazil and little is known about whether the existing inequality is due to socioeconomic factors or to racial discrimination per se. Data regarding the Ribeirão Preto birth cohort, Brazil, whose mothers were interviewed from June 1, 1978 to May 31, 1979 were used to answer these questions. The perinatal factors were obtained from the birth questionnaire and the ethnic data were obtained from 2063 participants asked about self-reported skin color at early adulthood (23-25 years of age) in 2002/2004. Mothers of mulatto and black children had higher rates of low schooling (£4 years, 27.2 and 38.0%) and lower family income (£1 minimum wage, 28.6 and 30.4%). Mothers aged less than 20 years old predominated among mulattos (17.0%) and blacks (14.0%). Higher rates of low birth weight and smoking during pregnancy were observed among mulatto individuals (9.6 and 28.8%). Preterm birth rate was higher among mulattos (9.5%) and blacks (9.7%) than whites (5.5%). White individuals had higher rates of cesarean delivery (34.9%). Skin color remained as an independent risk factor for low birth weight (P < 0.001), preterm birth (P = 0.01), small for gestational age (P = 0.01), and lack of prenatal care (P = 0.02) after adjustment for family income and maternal schooling, suggesting that the racial inequalities regarding these indicators are explained by the socioeconomic disadvantage experienced by mulattos and blacks but are also influenced by other factors, possibly by racial discrimination and/or genetics.

The fallacy of racial pharmacogenomics

Personalized pharmacogenomics aims to use individual genotypes to direct medical treatment. Unfortunately, the loci relevant for the pharmacokinetics and especially the pharmacodynamics of most drugs are still unknown. Moreover, we still do not understand the role that individual genotypes play in modulating the pathogenesis, the clinical course and the susceptibility to drugs of human diseases which, although appearing homogeneous on the surface, may vary from patient to patient. To try to deal with this situation, it has been proposed to use interpopulational variability as a reference for drug development and prescription, leading to the development of "race-targeted drugs". Given the present limitations of genomic knowledge and of the tools needed to fully implement it today, some investigators have proposed to use racial criteria as a palliative measure until personalized pharmacogenomics is fully developed. This was the rationale for the FDA approval of BiDil for treatment of heart failure in African Americans. I will evaluate the efficacy and safety of racial pharmacogenomics here and conclude that it fails on both counts. Next I shall review the perspectives and the predicted rate of development of clinical genomic studies. The conclusion is that "next-generation" genomic sequencing is advancing at a tremendous rate and that true personalized pharmacogenomics, based on individual genotyping, should soon become a clinical reality.